N J Meropol

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
    Neal J Meropol
    Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1452-8. 2003
  2. ncbi request reprint Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication
    Neal J Meropol
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:2589-96. 2003
  3. ncbi request reprint Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma
    N J Meropol
    Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, Pennslyvania, USA
    Cancer 91:1256-63. 2001
  4. ncbi request reprint Trimodality therapy for advanced gallbladder cancer
    A R Sasson
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am Surg 67:277-83; discussion 284. 2001
  5. doi request reprint Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
    C Aggarwal
    Department of Medicine, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 24:420-8. 2013
  6. doi request reprint Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
    S J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Ann Oncol 20:1223-9. 2009
  7. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
  8. ncbi request reprint A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
  9. ncbi request reprint Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas
    J F Pingpank
    Department of Suregery, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Gastrointest Surg 5:121-30. 2001
  10. ncbi request reprint Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
    N J Meropol
    Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 46:318-26. 1998

Collaborators

Detail Information

Publications73

  1. ncbi request reprint Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant
    Neal J Meropol
    Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1452-8. 2003
    ..To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer...
  2. ncbi request reprint Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication
    Neal J Meropol
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:2589-96. 2003
    ..To describe and compare the perceptions of cancer patients and their physicians regarding phase I clinical trials...
  3. ncbi request reprint Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma
    N J Meropol
    Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, Pennslyvania, USA
    Cancer 91:1256-63. 2001
    ..The goal of this study was to determine the antitumor activity and toxicity of an oral regimen containing eniluracil, 5-FU, and LV in patients with colorectal carcinoma...
  4. ncbi request reprint Trimodality therapy for advanced gallbladder cancer
    A R Sasson
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am Surg 67:277-83; discussion 284. 2001
    ..8 months (range 4-28 months). We conclude that trimodality therapy in selected patients with stage III, IV, or recurrent carcinoma of the gallbladder is possible and may result in prolonged survival...
  5. doi request reprint Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
    C Aggarwal
    Department of Medicine, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 24:420-8. 2013
    ..This secondary analysis assessed the relationship of the CTC number with carcinoembryonic antigen (CEA) and overall survival...
  6. doi request reprint Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
    S J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Ann Oncol 20:1223-9. 2009
    ..This analysis was undertaken to explore whether patient and treatment characteristics impact the prognostic value of CTCs...
  7. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
    ..Expression of AURKA protein was analysed by immunohistochemistry. Cox-proportional hazard method, Kaplan-Meier curves and log-rank statistics were used to estimate and compare the hazard ratios and median survival between the groups...
  8. ncbi request reprint A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
    ..Following a toxicity review of other trials using IFL, subsequent patients were enrolled at reduced doses of irinotecan (100 mg/m(2)) and 5-fluorouracil (400 mg/m(2))...
  9. ncbi request reprint Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas
    J F Pingpank
    Department of Suregery, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Gastrointest Surg 5:121-30. 2001
    ..06) and vein (P = 0.04) margins. However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07)...
  10. ncbi request reprint Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
    N J Meropol
    Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Immunol Immunother 46:318-26. 1998
    ....
  11. ncbi request reprint The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
    M von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 7:1181-91. 2001
    ....
  12. pmc The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial
    S M Miller
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Psychooncology 22:481-9. 2013
    ..Little is known about the relationship among knowledge, self-efficacy, preparation, decisional conflict, and patient decisions to take part in CCTs...
  13. ncbi request reprint Chemoprevention of colorectal cancer
    M L Clapper
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Curr Opin Oncol 13:307-13. 2001
    ....
  14. pmc Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 69:358-63. 2007
    ....
  15. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  16. ncbi request reprint Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer
    Gary M Freedman
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1389-93. 2007
    ..To determine the safety and efficacy of preoperative hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) and an incorporated boost with concurrent capecitabine in patients with locally advanced rectal cancer...
  17. ncbi request reprint Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status
    Elliot J Coups
    Division of Population Science, Fox Chase Cancer Center, 1st Floor, 510 Township Line Road, Cheltenham, PA 19012, USA
    Cancer Epidemiol Biomarkers Prev 16:510-6. 2007
    ..In the current study, we examined the prevalence, patterns, and predictors of multiple behavioral risk factors for colorectal cancer according to colorectal cancer screening status (adherent versus not adherent)...
  18. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  19. ncbi request reprint Cost of cancer care: issues and implications
    Neal J Meropol
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 25:180-6. 2007
    ..Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology...
  20. ncbi request reprint Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer
    Benjamin Movsas
    Henry Ford Health System, Radiation Oncology, Detroit, MI 48202, USA
    Am J Clin Oncol 29:435-41. 2006
    ..The purpose of this phase II study was to prospectively determine the efficacy of preoperative chemoradiation with a hyperfractionated (Hfx) RT boost to 61.8 Gy in locally advanced rectal cancer...
  21. ncbi request reprint Patients' decision-making process regarding participation in phase I oncology research
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 24:4479-84. 2006
    ..This study assesses the decision-making process of patients enrolling in phase I oncology studies...
  22. ncbi request reprint Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 6:125-32. 2006
    ....
  23. ncbi request reprint Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer
    Neal J Meropol
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 24:4069-77. 2006
    ....
  24. ncbi request reprint Turning point for colorectal cancer clinical trials
    Neal J Meropol
    J Clin Oncol 24:3322-4. 2006
  25. ncbi request reprint Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    J Randolph Hecht
    University of California School of Medicine, Los Angeles, CA, USA
    Cancer 110:980-8. 2007
    ..The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies...
  26. ncbi request reprint A renewed call for equipoise
    Neal J Meropol
    J Clin Oncol 25:3392-4. 2007
  27. ncbi request reprint Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
    ..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
  28. doi request reprint Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
    ....
  29. doi request reprint Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
    Daniel J Freeman
    Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Clin Colorectal Cancer 7:184-90. 2008
    ..Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone...
  30. doi request reprint Activity of sunitinib in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:3403-10. 2008
    ..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients...
  31. doi request reprint Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3213-21. 2008
    ..We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC...
  32. doi request reprint Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)
    Neal J Meropol
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3229-34. 2008
    ....
  33. pmc Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study
    Linda Fleisher
    Fox Chase Cancer Center, Philadelphia, PA 19012, United States
    Patient Educ Couns 71:378-87. 2008
    ..This paper highlights the development of a theory-guided, web-based communication aid (CONNECT), designed to facilitate treatment decision-making among patients with advanced cancer...
  34. doi request reprint Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 31:1-5. 2008
    ..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...
  35. ncbi request reprint An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study
    Joanne S Buzaglo
    Fox Chase Cancer Center, Divisions of Population Science, Philadelphia, PA, USA
    J Cancer Educ 22:233-40. 2007
    ..We therefore developed measures to assess patient communication preferences and established feasibility of an Internet-based intervention to improve communication...
  36. ncbi request reprint Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
    ..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
  37. ncbi request reprint Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer
    Sharon L Manne
    Division of Population and Medical Science, Fox Chase Cancer Center, 333 Cottman Avenue, P1100 Philadelphia, PA 19111, USA
    Cancer Epidemiol Biomarkers Prev 16:2110-7. 2007
    ..More distressed patients, patients who perceive themselves at higher risk for cancer recurrence, and patients with metastatic disease might be less motivated to have the MSI test...
  38. ncbi request reprint Barriers to clinical trial participation as perceived by oncologists and patients
    Neal J Meropol
    Divisions of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Compr Canc Netw 5:655-64. 2007
    ..We concluded that characterizing oncologist and patient perceived barriers can help improve communication and decision making about clinical trials, such that participation may be optimized...
  39. ncbi request reprint End points in advanced colon cancer clinical trials: a review and proposal
    Carmen Allegra
    University of Florida, Gainsville, FL, USA
    J Clin Oncol 25:3572-5. 2007
  40. ncbi request reprint Gastric Cancer Clinical Practice Guidelines
    Jaffer Ajani
    J Natl Compr Canc Netw 4:350-66. 2006
  41. ncbi request reprint Esophageal Cancer Clinical Practice Guidelines
    Jaffer Ajani
    J Natl Compr Canc Netw 4:328-47. 2006
  42. ncbi request reprint Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report
    Leonard R Henry
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 13:214-20. 2006
    ..On the basis of encouraging data from a phase I trial, we conducted a phase II study of preoperative chemotherapy, followed by concurrent chemoradiotherapy and surgery...
  43. pmc The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
    Salvatore Cortellino
    Program in Human Genetics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Proc Natl Acad Sci U S A 100:15071-6. 2003
    ..MED1 defects (much like MMR defects) may impair cell cycle arrest and apoptosis induced by DNA damage...
  44. ncbi request reprint The correlation between patient characteristics and expectations of benefit from Phase I clinical trials
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Cancer 98:166-75. 2003
    ..The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials...
  45. ncbi request reprint Drug development in pancreatic cancer: finally, biology begets therapy
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Gastrointest Cancer 32:91-106. 2002
    ..Currently, there is a renewed optimism that the clinical application of biologic understanding will lead to an improved outcome for patients with pancreatic cancer...
  46. ncbi request reprint 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology
    Lynn M Schuchter
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 20:2895-903. 2002
  47. ncbi request reprint Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
    ....
  48. ncbi request reprint Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care
    Jeanne S Mandelblatt
    Department of Oncology, Cancer Control Program, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
    J Clin Oncol 21:855-63. 2003
    ..There are few data on sequelae of breast cancer treatments in older women. We evaluated posttreatment quality of life and satisfaction in a national population...
  49. ncbi request reprint Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Fairooz Kabbinavar
    Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
    J Clin Oncol 21:60-5. 2003
    ....
  50. ncbi request reprint A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661
    Gini F Fleming
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:3718-27. 2002
    ..The purpose of this study was to determine the toxicity of escalating doses of trastuzumab when combined with a fixed dose regimen of interleukin (IL)-2...
  51. ncbi request reprint Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model
    Sharon Manne
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prev Med 36:71-84. 2003
    ....
  52. ncbi request reprint Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Cancer Chemother Pharmacol 50:257-65. 2002
    ..To determine the maximum tolerated dose (MTD) of raltitrexed when given with irinotecan and to evaluate the pharmacokinetics of these two agents when given in combination...
  53. ncbi request reprint Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 8:2116-22. 2002
    ....
  54. ncbi request reprint Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas
    Juan P Arnoletti
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am Surg 68:330-5; discussion 335-6. 2002
    ..In this poor-prognostic subset of patients with pancreatic cancer preoperative chemoradiation followed by an aggressive surgical approach was associated with resectability and long-term survival of a significant minority of patients...
  55. ncbi request reprint Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer
    Sharon Manne
    Division of Population Science, Fox Chase Cancer Center, Psycho Oncology Program, Philadelphia, Pennsylvania 19111, USA
    Health Psychol 21:3-15. 2002
    ..Physician and family recommendation were also strong correlates. A similar set of factors was associated with stage of adoption of CRC screening...
  56. ncbi request reprint Development of new agents for the treatment of advanced colorectal cancer
    Nancy L Lewis
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Clin Colorectal Cancer 3:154-64. 2003
    ..This article reviews these recent advances in the systemic treatment of colorectal cancer, including discussion of promising agents in clinical development...
  57. ncbi request reprint Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial
    Anthony F Shields
    Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 100:531-7. 2004
    ..The primary endpoint of the study was to determine the objective response rate, and a secondary endpoint was to measure the time to disease progression...
  58. ncbi request reprint Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 53:513-8. 2004
    ....
  59. ncbi request reprint Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol 32:S63-7. 2005
    ..Because response to preoperative treatment predicts clinical outcome, the utility of midtreatment PET scans to guide treatment decisions should be further explored in larger clinical studies...
  60. ncbi request reprint Changing patterns of bone and brain metastases in patients with colorectal cancer
    Mark L Sundermeyer
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 5:108-13. 2005
    ..This study was undertaken to test the hypothesis that expanded treatment options and resultant improved survival for patients with metastatic CRC are associated with an increased incidence of metastases at uncommon sites...
  61. ncbi request reprint A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorin
    Mary F Mulcahy
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Oncology 68:479-84. 2005
    ..This phase I study was undertaken to determine the maximally tolerated dose and dose-limiting toxicities of a combination of these drugs given in an ambulatory setting using a bolus schedule of 5-FU...
  62. ncbi request reprint Targeting signal transduction pathways in colorectal cancer--more than skin deep
    Steven J Cohen
    Division of Medical Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 23:5374-85. 2005
    ....
  63. ncbi request reprint Global gene expression profiling of circulating tumor cells
    Denis A Smirnov
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Cancer Res 65:4993-7. 2005
    ..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...
  64. ncbi request reprint Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction
    Wenchi Liang
    Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Oncol 20:1008-16. 2002
    ....
  65. ncbi request reprint UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
    Leslie E Carlini
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Clin Cancer Res 11:1226-36. 2005
    ....
  66. ncbi request reprint Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials
    Kevin P Weinfurt
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Cancer 103:140-7. 2005
    ..The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participation in Phase I oncology clinical trials...
  67. ncbi request reprint An exploration of relative health stock in advanced cancer patients
    Darrell J Gaskin
    Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland 21205, USA
    Med Decis Making 24:614-24. 2004
    ..Specifically, they estimated the effect of relative health stock on advanced cancer patients' decisions to participate in phase I clinical trials...
  68. ncbi request reprint Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome
    Aaron R Sasson
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gastrointest Cancer 34:121-8. 2003
    ..Although retrospective,this series suggests an improvement in survival in patients treated with neoadjuvant therapy...
  69. ncbi request reprint Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
    Nevena Damjanov
    Temple University, Fox Chase Temple Cancer Center, Philadelphia, Pennsylvania 19140, USA
    Oncology (Williston Park) 18:479-88; discussion 488, 493, 497 passim. 2004
    ....
  70. ncbi request reprint Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Leonard B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1201-8. 2004
    ..To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor...
  71. ncbi request reprint Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target
    Neal J Meropol
    J Clin Oncol 23:1791-3. 2005
  72. ncbi request reprint Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma
    Jeanne S Mandelblatt
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
    Cancer 95:2445-54. 2002
    ..There are few data on the long-term sequelae of axillary dissection among older breast carcinoma patients. We describe the impact of axillary dissection in a cohort of older women...
  73. ncbi request reprint Colorectal cancer: looking forward
    Neal J Meropol
    Semin Oncol 32:1-2. 2005